At this point in the war between Israel and Hamas, it’s difficult to get more than anecdotal evidence out of Gaza. Almost every organization that once provided aid and monitored civilian welfare is no longer allowed in — or has ceased operations. Very few journalists are left there.

But reports of a civilian population facing a hunger crisis are widespread.

To understand the reality on the ground, host David Gura talked to Bloomberg’s Israel bureau chief Ethan Bronner, UN reporter Magdalena Del Valle and Gaza reporter Fares Alghoul to understand how a hunger crisis unfolded there despite months of warnings.

Read more:

How Gaza Descended Into a Hunger Crisis, Explained

Israel Intends to Fully Take Over Gaza Despite Global Isolation

See omnystudio.com/listener for privacy information.

When a shortage of brand-name weight-loss drugs like Ozempic and Wegovy cleared the way for companies like Hims to fill the gap with cheaper, compounded versions, customers came flocking. But in February, the US Food and Drug Administration announced the shortage was over, leaving the company's strategy in flux and some investors worried.

On today’s Big Take podcast, host David Gura and Bloomberg healthcare reporter Madison Muller track how Hims became the king of copycat weight-loss drugs and what’s next for the company as it fights to hold onto the crown.

Read more: How Hims Became the King of Knockoff Weight-Loss Drugs

Cheap Ozempic Knockoffs Are Suddenly Everywhere. Are They Safe?

The Weight-Loss Drug Boom’s Prescription Problem

Listen and follow The Big Take on Apple Podcasts, Spotify or wherever you get your podcasts.

See omnystudio.com/listener for privacy information.

In an unusual deal, Nvidia and Advanced Micro Devices have agreed to pay the US government 15% of their revenue from AI chips they sell to China. The US has blocked the sale of other, more powerful chips to China on the basis of national security, but the exception underscores the Trump administration’s openness to make exceptions… if the price is right.

On today’s Big Take podcast, Bloomberg economic statecraft reporter Joe Deaux joins host Sarah Holder to explain the unprecedented nature of the deal, concerns about its legality and how it fits into Trump’s approach to trade with global competitors.

See omnystudio.com/listener for privacy information.